Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
Article excerpt
Highlighted: the sentence this signal was extracted from
In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Foundayo also reduced sleep apnea-specific hypoxic burden by up to an average of 55.9%, improving oxygen levels during sleep Lilly plans to submit Foundayo to the U.S. FDA for moderate-to-severe obstructive sleep apnea by the end of 2026 INDIANAPOLIS, Nov. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipron) in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with and without the use of positive airway pressure (PAP) therapy. At 52 weeks, Foundayo met the primary endpoint, significantly reducing the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity, as well as improving weight and other cardiovascular risk factors. 1 The results were presented today at the American Heart Association (AHA) Scientific Sessions 2026 and simultaneously published in JAMA. OSA affects an estimated 936 million adults worldwide, and most have never been diagnosed. 2 In people with OSA, the airway repeatedly collapses during sleep, causing drops in...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
